
|Articles|October 1, 2011
- Pharmaceutical Executive-10-01-2011
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - October 2011
Thirty Years of Pharm Exec
Advertisement
Articles in this issue
over 14 years ago
Y. K Hamied : Changing the Dialogueover 14 years ago
Fred Frank: Fortune and the Financierover 14 years ago
Marck McLellan: An 'A' for Advancing Expectationsover 14 years ago
Inside the Mind of the CEO: Steve Collisover 14 years ago
Atsushi Nagahisa: Creating Customer Valueover 14 years ago
Physicians: Still the Vital Connection in Medicineover 14 years ago
Henry Waxman: "Representing" Healthcare to the Fullestover 14 years ago
IP: Securing a Global Consensus—Can Industry Do It Again?over 14 years ago
In Establishing the Evidence Base, He Made Science Countover 14 years ago
Jane Henney: Lessons from the FDA Front LineNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
FDA Limits Regulations on Non-Medical Grade Wearable Fitness Devices
5




